MENU
MENU
MENU
MENU
About Norgine
Strategy
Corporate video
Partnering
Our work with patient organisations
Our work with healthcare professionals
Our integrated European model
Terms and conditions
Responsibility
Statement of Investment Principles
Modern Slavery Act Statement
Norgine UK Gender Pay Gap 2019
Norgine UK Gender Pay Gap 2018
Norgine UK Gender Pay Gap 2017
Norgine Business Code
Norgine House COVID19 Risk Assessment
Transparency and public declarations
Logo Here
Products
Clinical trial disclosure
Careers
Contact us
Locations
Report an adverse event
Ajinomoto Pharmaceuticals have filed an application for the manufacture and marketing authorisation of a new oral bowel cleansing agent in Japan
Share article:
Back to media releases
Next media release
29 February 2012
MOVIPREP-Japan-FINAL_1
We use strictly necessary, performance and functionality cookies to give you the best experience while using this website. We do not employ any marketing cookies on this website. Only continue if you accept.
Accept
Read more